Boston Scientific has since retired the Lotus Edge THV
A study of transcatheter aortic valve replacement (TAVR) procedures with the Lotus Edge transcatheter heart valve (THV) in 18 European centers yielded satisfactory short-term safety and efficacy, favorable hemodynamic results and low rates of paravalvular leak (PVL) in patients with complex anatomy. However, the rate of new permanent pacemaker (PPM) implantations remained high, according to the study, which was published Monday in JACC: Cardiovascular Interventions.